Business Context and Reporting Period
Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1996 (Fiscal Year 1997).
Business Overview: The Company operates through wholly-owned subsidiaries including Millennium Health International, Inc., CellLife International, Inc., and CellLife Pharmaceuticals International, Inc. It primarily engages in multi-level distribution of health and wellness products.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1996 |
Six Months Ended Dec 31, 1996 |
Six Months Ended Dec 31, 1995 |
|---|---|---|---|
| Net Sales | $12,630,234 | $24,067,255 | $22,107,755 |
| Gross Profit | $3,215,954 | $6,476,594 | $5,594,753 |
| Gross Margin % | 25.4% | 26.9% | 25.3% |
| Operating Income | $1,392,341 | $2,905,065 | $2,192,046 |
| Net Earnings | $849,292 | $1,749,665 | $1,324,286 |
| Earnings Per Share (Diluted) | $0.15 | $0.31 | $0.24 |
| Cash and Equivalents | $3,483,474 | $3,483,474 | $2,471,195 |
| Working Capital | $12,144,061 | $12,144,061 | $10,990,450 |
| Total Debt (Current + Long-term) | $1,438,150 | $1,438,150 | $1,510,854 |
Note: Total Debt includes current installments of long-term debt ($230,200), capital lease obligations ($24,202), line of credit ($443,959), and long-term debt less current installments ($1,177,748) plus capital lease obligations less current installments ($36,612).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.5% for the quarter and 8.9% for the six-month period compared to the prior year, driven primarily by increased sales to existing customers.
- Margin Expansion: Gross profit margins improved to 25.4% (quarter) and 26.9% (six months) from 24.7% and 25.3% respectively, attributed to a favorable change in sales mix.
- International Sales Decline: International sales decreased significantly to $0.5 million for the quarter (from $0.9 million) and $0.8 million for the six months (from $1.8 million). Management cites customer inventory build-ups prior to the fiscal year and a restructuring of European ownership.
- Liquidity Position: Cash and cash equivalents increased by $1.6 million to $3.5 million. Working capital increased by approximately $1.15 million, driven by a $1.2 million increase in accounts payable and a $0.5 million increase in inventory.
- Debt Utilization: The Company drew $444,000 on its revolving line of credit during the period, whereas no borrowings existed at June 30, 1996.
Outlook, Risks, and Management Commentary
- Capital Expenditures: The Company has purchase commitments of approximately $500,000 for production equipment and expects to spend $200,000 on laboratory expansion and leasehold improvements in the third quarter. These are expected to be funded by operating cash flow and credit lines.
- Liquidity Strategy: Management believes internally generated cash flow and existing credit facilities (up to $3,000,000 secured by receivables, inventory, and equipment) are sufficient to fund operations and growth. The credit lines expire December 5, 1997, and are expected to be renewed.
- Customer Concentration Risk: The Company relies heavily on three major customers. For the six months ended December 31, 1996, 64% of revenue came from the Multi-level Distribution segment, with substantial sales concentrated in a few accounts. The loss of any of these customers would have an adverse short-term impact.
- Legal Proceedings: The Company is involved in various ordinary course legal actions, but management does not anticipate a material adverse impact on financial position.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the top three customers, given they represent a significant portion of revenue and the recent decline in international sales.
- Inventory Levels: Monitor inventory turnover, as inventory increased by $0.5 million while management noted working off prior build-ups.
- Credit Line Renewal: Confirm the renewal status of the $3,000,000 revolving credit facility expiring in December 1997.
- International Restructuring: Assess the long-term impact of the European ownership restructuring on future international revenue streams.
- Capital Expenditure Execution: Track the deployment of the $700,000 in committed capital expenditures for equipment and lab expansion in the upcoming quarter.